ATROPEN Drug Patent Profile

« Back to Dashboard

When do Atropen patents expire, and what generic alternatives are available?

Atropen is a drug marketed by MMT and is included in one NDA.

The generic ingredient in ATROPEN is atropine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine profile page.

Summary for ATROPEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	3
Patent Applications:	2,090
DailyMed Link:	ATROPEN at DailyMed

Recent Clinical Trials for ATROPEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Manitoba	Phase 4
Craig J. Huang	N/A
U.S. Army Space and Missile Defense Command	Phase 1

See all ATROPEN clinical trials

Pharmacology for ATROPEN

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Antagonists Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for ATROPEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-004	Sep 17, 2004		DISCN	Yes	No
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-003	Jun 19, 2003		DISCN	Yes	No

ATROPEN Market Dynamics, Financial Trajectory, Patent Position, and Generic Entry Risk

Last updated: November 5, 2026

ATROPEN is an atropine sulfate auto-injector used for emergency treatment of organophosphate nerve-agent poisoning. Its market is driven primarily by government preparedness programs, military procurement, and stockpile replenishment rather than routine retail prescriptions. Pfizer’s public filings do not report ATROPEN revenue separately, and no public source provides product-level sales, market share, or profitability.

The product remains strategically relevant because atropine is a core countermeasure for chemical-agent exposure. Its commercial outlook depends on federal and defense contracts, procurement policy, inventory rotation, manufacturing capacity, and competition from multidrug autoinjectors such as DuoDote and ATNAA.

What is ATROPEN and who manufactures it?

ATROPEN is a single-drug atropine sulfate auto-injector manufactured by Meridian Medical Technologies, Inc., a Pfizer company. The product is available in multiple strengths designed for weight- and age-based dosing. FDA labeling identifies ATROPEN for emergency treatment of poisoning by susceptible organophosphorus nerve agents and insecticides, with use of pralidoxime and other supportive measures when clinically indicated.[1]

Product	Active ingredient	Delivery system	Primary use	Manufacturer
ATROPEN	Atropine sulfate	Single-use auto-injector	Organophosphate nerve-agent poisoning	Meridian Medical Technologies, a Pfizer company
DuoDote	Atropine sulfate plus pralidoxime chloride	Dual-chamber auto-injector	Nerve-agent poisoning	Emergent BioSolutions
ATNAA	Atropine sulfate plus pralidoxime chloride	Dual-chamber auto-injector	Nerve-agent poisoning	Meridian Medical Technologies
Atropine injection	Atropine sulfate	Vial, syringe, or other injectable format	Broad clinical uses, including poisoning	Multiple manufacturers

ATROPEN differs from DuoDote and ATNAA because it supplies atropine alone. This can simplify dosing when pralidoxime is supplied separately, but it also exposes the product to competition from combination devices used in military and emergency-response kits.

What is the FDA regulatory status of ATROPEN?

ATROPEN is associated with FDA New Drug Application No. 020608. FDA labeling describes the product as an atropine sulfate injection delivered through an auto-injector for emergency treatment of organophosphorus poisoning.[1][2]

The regulatory status has several commercial implications:

1. ATROPEN is an FDA-approved drug-device combination product.
2. Its active ingredient, atropine sulfate, is an established generic molecule.
3. The principal product differentiation is the delivery device, dose presentation, packaging, labeling, and procurement qualification.
4. The product is not a biologic and does not face biosimilar competition.
5. Routine clinical demand for atropine does not translate directly into demand for the ATROPEN device.

FDA’s Drugs@FDA database and approved labeling are the primary public sources for the product’s application and safety information.[2]

What is the market size for ATROPEN?

No reliable public source reports a standalone ATROPEN market size. The relevant market is narrower than the overall atropine market and consists mainly of:

• U.S. military and defense agencies.
• Federal civilian preparedness programs.
• State and local emergency-response agencies.
• Industrial facilities with organophosphate exposure risks.
• International military and civil-defense purchasers.
• Specialized medical distributors.

ATROPEN is not primarily a hospital atropine product. Hospitals generally purchase lower-cost atropine vials, prefilled syringes, or other injectable presentations for cardiac and emergency use. Auto-injectors command a premium because they provide rapid administration, reduce preparation time, and can be used by personnel with limited medical training.

The addressable market is therefore determined by the number of protected personnel, stockpile requirements, replacement cycles, and the number of devices maintained in strategic inventories. It is not determined by the much larger clinical market for atropine sulfate.

How does ATROPEN generate revenue?

ATROPEN revenue is likely concentrated in institutional contracts rather than recurring retail prescriptions. Pfizer reports broad business segments and selected product sales but does not disclose ATROPEN as a separate revenue line in its public annual reports.[3]

The product’s revenue model has four main components:

Revenue driver	Effect on ATROPEN
Initial procurement	Creates large but irregular orders when agencies build or expand inventories
Stockpile replacement	Supports recurring demand as devices approach expiry
Contract renewals	Determines visibility and customer concentration
Emergency replenishment	Produces episodic demand after geopolitical or chemical-exposure events

Government procurement can produce substantial order variability. A single multiyear award may increase production and revenue for a limited period, followed by a lower-volume maintenance phase. This pattern makes annual revenue difficult to forecast from prescription data.

What is the financial trajectory for ATROPEN?

ATROPEN’s product-level financial trajectory is not publicly quantifiable because Pfizer does not disclose net sales, gross margin, operating income, backlog, or contract value for the product.

The commercial trajectory can nevertheless be characterized as mature and procurement-driven:

Early commercialization

ATROPEN entered the market as a specialized delivery platform for atropine. Its value proposition was rapid, standardized administration in situations where conventional syringes could be impractical.

Mature market phase

The active pharmaceutical ingredient is inexpensive and widely available. Economic value shifted toward the device, manufacturing process, government qualification, packaging, shelf life, and supply assurance. This limits pricing power compared with innovative therapeutics.

Current revenue profile

Current demand is likely supported by:

• Replacement of expiring emergency inventories.
• Defense preparedness programs.
• Chemical-threat assessments.
• International security procurement.
• Requirements for deployable medical countermeasures.

Revenue is likely pressured by:

• Competition from combination autoinjectors.
• Lower-cost atropine presentations.
• Government purchasing cycles.
• Contract concentration.
• Device manufacturing and quality-control costs.
• The absence of routine outpatient demand.

ATROPEN should therefore be valued as a specialized medical-countermeasure product rather than as a conventional branded pharmaceutical with broad prescription growth.

What patents protect ATROPEN?

Public FDA sources do not establish a current, commercially material Orange Book patent estate for ATROPEN. The underlying molecule, atropine sulfate, is an old generic active ingredient, and any early composition-of-matter protection would have expired long ago.

Potential historical or non-Orange-Book protection could have involved:

• Auto-injector mechanics.
• Dose-selection architecture.
• Safety mechanisms.
• Drug-device integration.
• Packaging and shipping systems.
• Manufacturing processes.
• Shelf-life or stability improvements.

The existence of device or process patents would not necessarily block a competing atropine auto-injector. Patent claims would need to cover the specific device architecture, drug configuration, or manufacturing method used by the competitor.

IP category	Current commercial relevance
Atropine molecule	Low; long-established generic compound
Basic atropine formulation	Low unless tied to a specific device or stability claim
Auto-injector mechanism	Potentially relevant, depending on claim scope and expiration
Dose-specific presentation	Limited protection unless technically distinctive
Packaging and shelf-life	Can create operational advantages but may not block competitors
Manufacturing know-how	Potential barrier even without enforceable patent exclusivity

No active patent number, expiration date, or enforceable claim should be attributed to ATROPEN without a current patent-register and family-level review. FDA Orange Book listings, where available, provide the relevant regulatory patent record for approved drug products.[4]

When does ATROPEN lose exclusivity?

ATROPEN’s practical exclusivity is not determined solely by the expiry of a drug patent. The product’s effective protection has several layers:

1. Regulatory approval for the specific product.
2. Device engineering and human-factors performance.
3. Manufacturing validation.
4. Government qualification and procurement history.
5. Institutional switching costs.
6. Supply reliability.
7. Any remaining device or process patents.

The atropine active ingredient has no meaningful new-molecule exclusivity. Any original ATROPEN regulatory exclusivity would have expired many years ago, given the product’s 1990s approval history.

The principal remaining commercial barrier is execution rather than molecule-level exclusivity. A competitor must produce a reliable, FDA-compliant auto-injector, secure approval, demonstrate usability, establish supply capacity, and win government contracts.

What is the Orange Book status of ATROPEN?

The Orange Book is relevant to ATROPEN because it identifies FDA-approved drug applications and any listed patents or exclusivity information. Publicly available FDA records do not indicate that ATROPEN has a current market-blocking patent position comparable to newer branded medicines.[4]

The absence of a meaningful Orange Book barrier has two implications:

• A competing applicant may be able to pursue an abbreviated or full approval strategy without waiting for a long patent term.
• FDA approval alone would not guarantee commercial access, because federal procurement qualification and device performance remain critical.

The legal pathway for a competitor depends on the product’s regulatory classification, formulation, delivery system, and degree of equivalence. An atropine injection in a vial is not automatically substitutable for an atropine auto-injector.

Which companies are challenging ATROPEN?

No publicly established Paragraph IV litigation or major patent challenge against ATROPEN is identified in the core FDA and public company materials reviewed for this analysis.

Competition is more likely to arise through product substitution and contract bidding than through patent litigation. Relevant competitors include:

• Emergent BioSolutions, through DuoDote.
• Meridian Medical Technologies, through ATNAA and related countermeasure products.
• Generic injectable atropine manufacturers.
• Device manufacturers developing alternative autoinjectors.
• International suppliers of atropine and nerve-agent countermeasure kits.

A conventional ANDA applicant could face technical and regulatory issues if its product is not sufficiently equivalent in device operation, delivered dose, labeling, or emergency-use instructions. A full NDA or 505(b)(2) pathway may be more appropriate for a materially different device or combination product, depending on FDA requirements.

What formulation and device patents matter most?

The most commercially relevant protection would not be a basic atropine formulation. It would be protection covering the integrated delivery system.

Auto-injector design

Relevant claims could cover activation force, needle deployment, dose delivery, user safety, tamper resistance, and prevention of accidental injection.

Dose architecture

A product with multiple fixed strengths can simplify field use but increases manufacturing complexity and inventory requirements. Claims directed to dose-specific cartridges or drug-device configurations could affect competition.

Stability and shelf life

Government stockpiles require long shelf life and predictable performance under demanding storage conditions. Stability improvements may produce procurement advantages even when they do not provide broad patent exclusivity.

Manufacturing and assembly

Sterile filling, cartridge assembly, device integration, and final product testing are potential operational barriers. These capabilities may be protected through trade secrets, process controls, or regulatory know-how rather than patents.

What generic entry risks exist for ATROPEN?

Generic entry risk is moderate for the active ingredient but lower for a fully equivalent auto-injector.

Risk area	Assessment
Atropine ingredient competition	High
Conventional injectable competition	High
Equivalent auto-injector competition	Moderate
Combination-device competition	Moderate to high
Patent-based blocking position	Low based on public FDA information
Government contract displacement	Moderate
Biosimilar risk	Not applicable
Manufacturing substitution	Moderate

A generic atropine vial does not replicate ATROPEN’s emergency-use function. The most credible competitive threat is a functionally equivalent atropine auto-injector or a combination device that wins the same government procurement opportunity.

What patent litigation affects ATROPEN?

No significant publicly reported patent litigation affecting ATROPEN has been identified in the principal FDA and public corporate sources. The absence of litigation is consistent with the product’s mature status, limited patent value, and procurement-centered market.

Future disputes would more likely concern:

• Device patent infringement.
• Contract awards.
• Product substitution.
• Regulatory equivalence.
• Supply and quality obligations.
• Government pricing or procurement terms.

A patent case would have limited commercial value unless the asserted claims covered a core, difficult-to-design-around component of the auto-injector.

How does ATROPEN compare with DuoDote and ATNAA?

Factor	ATROPEN	DuoDote	ATNAA
Active ingredients	Atropine only	Atropine plus pralidoxime	Atropine plus pralidoxime
Product type	Single-drug auto-injector	Combination auto-injector	Combination auto-injector
Main advantage	Flexible atropine-only dosing	Integrated nerve-agent treatment	Integrated nerve-agent treatment
Main limitation	Pralidoxime must be supplied separately when required	Less flexibility where atropine alone is preferred	Combination-device procurement dependence
Commercial buyer	Defense and emergency agencies	Defense and emergency agencies	Defense and emergency agencies
Biosimilar exposure	None	None	None
Generic substitution	Limited by device	Limited by device	Limited by device

Combination autoinjectors can reduce the number of separate devices in a field kit. ATROPEN can remain attractive where protocols call for atropine-only administration, where pralidoxime is supplied separately, or where agencies maintain mixed inventories.

What geographic markets support ATROPEN?

The United States is likely the most important market because of federal preparedness programs and the role of U.S. defense agencies in chemical-countermeasure procurement. International demand may arise from:

• NATO-aligned military forces.
• Civil-defense agencies.
• Countries with chemical-industry exposure risks.
• Governments seeking emergency medical countermeasures.
• Humanitarian and industrial-response organizations.

Geographic expansion is constrained by local regulatory approvals, government tenders, import rules, training requirements, and national stockpile policies. Public financial reporting does not separate ATROPEN sales by geography.

What generic launch scenarios are most likely?

Three launch scenarios are commercially plausible:

1. A competing atropine auto-injector enters through an FDA pathway and competes for government contracts. This would create the greatest direct pressure.
2. A combination atropine-pralidoxime device displaces single-drug autoinjectors in selected procurement programs.
3. Injectable atropine suppliers compete for lower-acuity or medically staffed settings, leaving ATROPEN concentrated in field-response applications.

A generic entrant would need more than a low-cost active ingredient. It would need device reliability, shelf-life validation, emergency-use labeling, production scale, and procurement acceptance.

Key Takeaways

• ATROPEN is a mature atropine sulfate auto-injector used mainly for nerve-agent and organophosphate poisoning.
• Pfizer does not separately disclose ATROPEN revenue, profit, backlog, or market share.
• The product’s financial trajectory is linked to government procurement, stockpile replenishment, and defense readiness rather than routine prescriptions.
• Atropine itself has no meaningful new-molecule exclusivity.
• Public FDA information does not show a current market-blocking Orange Book patent estate.
• The key competitive barriers are device engineering, regulatory approval, manufacturing qualification, shelf life, and government contracting.
• Direct generic risk is low for conventional atropine substitution but moderate for an equivalent auto-injector.
• DuoDote and ATNAA are the principal product-level comparators because they combine atropine with pralidoxime.
• Biosimilar risk is not applicable because ATROPEN is a small-molecule drug product.
• The most important commercial risk is contract displacement by combination devices or competing atropine autoinjectors.

FAQs

Is ATROPEN still available?

ATROPEN has an FDA-approved product history and remains associated with Meridian Medical Technologies, a Pfizer company. Commercial availability can vary by government contract, distributor inventory, and procurement cycle.

Is ATROPEN interchangeable with a regular atropine syringe?

No. A regular atropine syringe may contain the same active ingredient but does not provide the same integrated delivery system, labeling, packaging, or emergency-use functionality.

Does ATROPEN have biosimilar competition?

No. Atropine sulfate is a small-molecule drug, so the relevant competitive pathways are generic drug and drug-device products, not biosimilars.

Can a generic manufacturer copy the ATROPEN device?

A competitor may develop an alternative device, but it must satisfy FDA requirements for drug-device performance, dose delivery, usability, safety, manufacturing quality, and labeling. Any surviving device patents or proprietary manufacturing rights would also require evaluation.

Why is ATROPEN commercially important if atropine is inexpensive?

The commercial value is in rapid, reliable field delivery under emergency conditions. The auto-injector, packaging, shelf life, training requirements, and procurement qualification create value beyond the low cost of atropine sulfate itself.

References

1. U.S. Food and Drug Administration. (n.d.). ATROPEN (atropine injection) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
3. Pfizer Inc. (2024). 2023 annual report. Pfizer.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.